Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1 Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $2.77B |
| Revenue Growth (YOY): 11.61% |
| Profit (% of Rev): 85.84% |
| Income (% of Rev): 37.71% |
| Income Growth (YOY): 0.98% |
| Operating Income: $1.12B |
| Operating Cash Flow: $1.37B |
| Operating Cash Flow Growth (YoY): 7.99% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $22.24B |
| Total Liabilities: $6.61B |
| Cash & Equivalent: $5.24B |
| Total Debt: $1.70B |
| Debt/Equity: 0.09 |
| Quick Ratio: 2.20 |
| Current Ratio: 2.47 |
| Price/Book: 7.68 |
| Price/Earnings: 28.69 |
| EBITDA: $1.12B |
| EPS: 4.05 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.